Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Carparts.Com Inc (PRTS) Price & Performance

Enveric Biosciences IncTrade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Carparts.Com Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Carparts.Com Inc trades at $6.41 (market cap $52.07M). The key difference: Carparts.Com Inc is far larger — about 8.4× Enveric Biosciences Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBPRTS
Market Cap
$6.20M$52.07M
Sector
HealthConsumer Cyclical
52-Week High
$17.40$11.40
52-Week Low
$1.27$3.88
Enterprise Value
$1.30M$67.05M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Carparts.Com Inc

CarParts.com (PRTS) is trading at $6.75, up 16.68% with bullish technical signals and strong analyst support. The company shows improving operational performance with three consecutive quarterly earnings beats, though it remains unprofitable with negative net margins. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25 million credit facility, providing financial flexibility amid challenging market conditions.

The outlook remains cautiously optimistic with 60% analyst buy ratings supporting recovery potential, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investors should focus on the company's ability to leverage proprietary data advantages while monitoring progress toward profitability in the competitive auto parts e-commerce sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS